Phase I-Ii Open Label Multicenter Study Of Pd0332991 In Braf(V600mut) Metastatic Melanoma Patients Harboring Cdkn2a Loss And Rb1 Expression And Treated With Vemurafenib.

Baptiste Louveau,Matthieu Resche-Rigon,Thierry Lesimple,Marc Pracht,Barouyr Baroudjian,Julie Delyon,Fanelie Jouenne,Mona Amini-Adle,Caroline Dutriaux,Laetitia Da Meda,Zineb Ghrieb,Didier Bouton,Annick Tibi,Samuel Huguet,Keyvan Rezai,Maxime Battistella,Samia Mourah,Celeste Lebbe

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 3|浏览39

暂无评分

摘要

9545Background: Among mechanisms of resistance to BRAF inhibitors (BRAFi), cell cycle effectors including CDK4 have been involved in ERK reactivation. In this phase I-II open label study, we aimed ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要